Schizophrenia is a severe mental disorder characterized by disturbances in thought, perception, and behavior. Early diagnosis plays a crucial role in improving treatment outcomes and quality of life for patients. In recent years, the use of biomarkers — including genetic, neuroimaging, and biochemical indicators — has become a promising approach for identifying schizophrenia in its early stages. This article reviews the current state of research on biomarkers and their potential in facilitating early detection and personalized treatment strategies.

Schizophrenia, biomarkers, early diagnosis, neuroimaging, genetics, psychiatry

Andreasen, N. C. (2020). Schizophrenia and the neurodevelopmental paradigm: A 21st-century perspective. American Journal of Psychiatry, 177(12), 1115–1128.

Cervenka, S., Hedman, E., & Farde, L. (2019). Biomarkers for schizophrenia: Progress and challenges. Frontiers in Psychiatry, 10, 412.

Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., ... & Insel, T. R. (2015). Schizophrenia. Nature Reviews Disease Primers, 1(1), 15067.

Radua, J., Borgwardt, L., Crescini, A., et al. (2018). Multimodal meta-analysis of structural and functional brain changes in first-episode psychosis and high-risk states. Neuroscience & Biobehavioral Reviews, 92, 56–68.

van Os, J., & Reininghaus, U. (2016). Psychosis as a transdiagnostic and extended phenotype in the general population. World Psychiatry, 15(2), 118–124.

Upthegrove, R., Manzanares-Teson, N., & Barnes, N. M. (2014). Cytokine function in medication-naïve first episode psychosis: A systematic review and meta-analysis. Schizophrenia Research, 155(1-3), 101–108.

World Health Organization. (2022). Schizophrenia fact sheet. Retrieved from https://www.who.int/news-room/fact-sheets/detail/schizophrenia